References
- Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, et al. State of the science: an update on renal cell carcinoma. Mol Cancer Res 2012; 10(7): 859–80; PMID:22638109; https://doi.org/10.1158/1541-7786.MCR-12-0117
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1): 11–30; PMID:23335087; https://doi.org/10.3322/caac.21166
- Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ 2014; 349: g4797; PMID:25385470; https://doi.org/10.1136/bmj.g4797
- Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Marechal JM, Klotz L, Skinner E, Keane T, et al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2007; 51(6): 1606–15; PMID:17140723; https://doi.org/10.1016/j.eururo.2006.11.013
- Thomas JS, Kabbinavar F. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies. Crit Rev Oncol Hematol 2015; 96(3): 527–33; PMID:26299335; https://doi.org/10.1016/j.critrevonc.2015.07.009
- Skolarikos A, Alivizatos G, Laguna P, de la Rosette J. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol 2007; 51(6): 1490–500; discussion 501; PMID:17229521; https://doi.org/10.1016/j.eururo.2006.12.031
- Fendler A, Jung K. MicroRNAs as new diagnostic and prognostic biomarkers in urological tumors. Crit Rev Oncog 2013; 18(4): 289–302; PMID:23614616;
- Fendler A, Stephan C, Yousef GM, Jung K. MicroRNAs as regulators of signal transduction in urological tumors. Clin Chem 2011; 57(7): 954–68; PMID:21632885; https://doi.org/10.1373/clinchem.2010.157727
- Gao Y, Ma X, Yao Y, Li H, Fan Y, Zhang Y, Zhao C, Wang L, Ma M, Lei Z, et al. miR-155 regulates the proliferation and invasion of clear cell renal cell carcinoma cells by targeting E2F2. Oncotarget 2016; 7(15): 20324–37; PMID:26967247; https://doi.org/10.18632/oncotarget.7951
- Wotschofsky Z, Gummlich L, Liep J, Stephan C, Kilic E, Jung K, Billaud JN, Meyer HA. Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p. PLoS One 2016; 11(2): e0148746; PMID:26859141; https://doi.org/10.1371/journal.pone.0148746
- Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer 2014; 14: 80; PMID:24512620; https://doi.org/10.1186/1471-2407-14-80
- Chang JT, Wang F, Chapin W, Huang RS. Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. PLoS One 2016; 11(12): e0168284; PMID:27959953; https://doi.org/10.1371/journal.pone.0168284
- Butz H, Szabo PM, Khella HW, Nofech-Mozes R, Patocs A, Yousef GM. miRNA-target network reveals miR-124as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1. Oncotarget 2015; 6(14): 12543–57; PMID:26002553; https://doi.org/10.18632/oncotarget.3815
- Gonzalez-Burgos G. GABA transporter GAT1: a crucial determinant of GABAB receptor activation in cortical circuits? Adv Pharmacol 2010; 58: 175–204; PMID:20655483; https://doi.org/10.1016/S1054-3589(10)58008-6
- Carvill GL, McMahon JM, Schneider A, Zemel M, Myers CT, Saykally J, Nguyen J, Robbiano A, Zara F, Specchio N, et al. Mutations in the GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-Atonic Seizures. Am J Hum Genet 2015; 96(5): 808–15; PMID:25865495; https://doi.org/10.1016/j.ajhg.2015.02.016
- Schijns O, Karaca U, Andrade P, de Nijs L, Kusters B, Peeters A, Dings J, Pannek H, Ebner A, Rijkers K, et al. Hippocampal GABA transporter distribution in patients with temporal lobe epilepsy and hippocampal sclerosis. J Chem Neuroanat 2015; 68: 39–44; PMID:26212582; https://doi.org/10.1016/j.jchemneu.2015.07.004
- Curley AA, Eggan SM, Lazarus MS, Huang ZJ, Volk DW, Lewis DA. Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: implications for schizophrenia. Neurobiol Dis 2013; 50: 179–86; PMID:23103418; https://doi.org/10.1016/j.nbd.2012.10.018
- Januchowski R, Zawierucha P, Andrzejewska M, Rucinski M, Zabel M. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed Pharmacother 2013; 67(3): 240–5; PMID:23462296; https://doi.org/10.1016/j.biopha.2012.11.011
- Kim KR, Oh SY, Park UC, Wang JH, Lee JD, Kweon HJ, Kim SY, Park SH, Choi DK, Kim CG, et al. [Gene expression profiling using oligonucleotide microarray in atrophic gastritis and intestinal metaplasia]. Korean J Gastroenterol 2007; 49(4): 209–24; PMID:17464166;
- Sipila S, Huttu K, Voipio J, Kaila K. GABA uptake via GABA transporter-1 modulates GABAergic transmission in the immature hippocampus. J Neurosci 2004; 24(26): 5877–80; PMID:15229234; https://doi.org/10.1523/JNEUROSCI.1287-04.2004
- Ganapathi MK, Jones WD, Sehouli J, Michener CM, Braicu IE, Norris EJ, Biscotti CV, Vaziri SA, Ganapathi RN. Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer. Int J Cancer 2016; 138(3): 679–88; PMID:26311224; https://doi.org/10.1002/ijc.29815
- Karunakaran S, Umapathy NS, Thangaraju M, Hatanaka T, Itagaki S, Munn DH, Prasad PD, Ganapathy V. Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy. Biochem J 2008; 414(3): 343–55; PMID:18522536; https://doi.org/10.1042/BJ20080622
- Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, Pilarsky C, Johannsen M, Stephan C, Lehrach H, et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 2009; 13(9B): 3918–28; PMID:19228262; https://doi.org/10.1111/j.1582-4934.2009.00705.x
- Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol 2008; 216(4): 418–27; PMID:18925646; https://doi.org/10.1002/path.2437
- Wang X, Chen L, Jin H, Wang S, Zhang Y, Tang X, Tang G. Screening miRNAs for early diagnosis of colorectal cancer by small RNA deep sequencing and evaluation in a Chinese patient population. Onco Targets Ther 2016; 9: 1159–66; PMID:27022275; https://doi.org/10.2147/OTT.S100427
- Zhang L, Huang Z, Zhang H, Zhu M, Zhu W, Zhou X, Liu P. Prognostic value of candidate microRNAs in gastric cancer: A validation study. Cancer Biomark 2017; 18(3): 221–30; PMID:27983528; https://doi.org/10.3233/CBM-160091
- Teng Y, Su X, Zhang X, Zhang Y, Li C, Niu W, Liu C, Qu K. miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations. Oncotarget 2016; 7(49): 81621–33; PMID:27835595; https://doi.org/10.18632/oncotarget.13154
- Wang X, Chen X, Wang R, Xiao P, Xu Z, Chen L, Hang W, Ruan A, Yang H, Zhang X. microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis. Oncol Rep 2013; 30(2): 643–50; PMID:23754305; https://doi.org/10.3892/or.2013.2530
- Yoshino H, Enokida H, Itesako T, Tatarano S, Kinoshita T, Fuse M, Kojima S, Nakagawa M, Seki N. Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. J Hum Genet 2013; 58(8): 508–16; PMID:23635949; https://doi.org/10.1038/jhg.2013.31
- Capri M, Olivieri F, Lanzarini C, Remondini D, Borelli V, Lazzarini R, Graciotti L, Albertini MC, Bellavista E, Santoro A, et al. Identification of miR-31-5p, miR-141-3p, miR-200c-3p, and GLT1 as human liver aging markers sensitive to donor-recipient age-mismatch in transplants. Aging Cell 2017; 16(2): 262–72; PMID:27995756; https://doi.org/10.1111/acel.12549
- Mody HR, Hung SW, Naidu K, Lee H, Gilbert CA, Hoang TT, Pathak RK, Manoharan R, Muruganandan S, Govindarajan R. SET contributes to the epithelial-mesenchymal transition of pancreatic cancer. Oncotarget 2017; 8(40): 67966–79; PMID:28978088; https://doi.org/10.18632/oncotarget.19067
- Hu WW, Chen PC, Chen JM, Wu YM, Liu PY, Lu CH, Lin YF, Tang CH, Chao CC. Periostin promotes epithelial-mesenchymal transition via the MAPK/miR-381 axis in lung cancer. Oncotarget 2017; 8(37): 62248–60; PMID:28977942; https://doi.org/10.18632/oncotarget.19273
- Shin S, Im HJ, Kwon YJ, Ye DJ, Baek HS, Kim D, Choi HK, Chun YJ. Human steroid sulfatase induces Wnt/beta-catenin signaling and epithelial-mesenchymal transition by upregulating Twist1 and HIF-1alpha in human prostate and cervical cancer cells. Oncotarget 2017; 8(37): 61604–17; PMID:28977889; https://doi.org/10.18632/oncotarget.18645
- Liu F, Wu L, Wang A, Xu Y, Luo X, Liu X, Hua Y, Zhang D, Wu S, Lin T, et al. MicroRNA-138 attenuates epithelial-to-mesenchymal transition by targeting SOX4 in clear cell renal cell carcinoma. Am J Transl Res 2017; 9(8): 3611–22; PMID:28861152;
- Chen Q, Yang D, Zong H, Zhu L, Wang L, Wang X, Zhu X, Song X, Wang J. Growth-induced stress enhances epithelial-mesenchymal transition induced by IL-6 in clear cell renal cell carcinoma via the Akt/GSK-3beta/beta-catenin signaling pathway. Oncogenesis 2017; 6(8): e375; PMID:28846080; https://doi.org/10.1038/oncsis.2017.74
- Jiang J, Yi BO, Ding S, Sun J, Cao W, Liu M. Demethylation drug 5-Aza-2'-deoxycytidine-induced upregulation of miR-200c inhibits the migration, invasion and epithelial-mesenchymal transition of clear cell renal cell carcinoma in vitro. Oncol Lett 2016; 11(5): 3167–72; PMID:27123083; https://doi.org/10.3892/ol.2016.4364